TrialCurveFOCUS4-D: reconstructed Kaplan–Meier curves
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Gastroenterol Hepatol. 2017 Dec 16;3(3):162–71. doi: 10.1016/S2468-1253(17)30394-1 |
|---|---|
| DOI | 10.1016/S2468-1253(17)30394-1 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Intention-to-treat
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Placebo 3.5 months; AZD8931 3.0 months. Survival at 4 months: Placebo 38%; AZD8931 38%. Hazard ratio Placebo vs AZD8931 1.06 (95% CI 0.51–2.20).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Placebo | 16 | 16 | 3.5 |
| AZD8931 | 16 | 15 | 3.0 |
- Placebo vs AZD8931: reconstructed HR 1.06 (95% CI 0.51–2.20)
Landmark survival (reconstructed)
| Time | Placebo | AZD8931 |
|---|---|---|
| 2 mo | 56.2% | 75.0% |
| 4 mo | 37.5% | 37.5% |
| 6 mo | 12.5% | 22.5% |
| 8 mo | 12.5% | — |
| 10 mo | 12.5% | — |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.1, reconstructed 1.06 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/focus4-d-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/focus4-d-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Gastroenterol Hepatol. 2017 Dec 16;3(3):162–71. doi: 10.1016/S2468-1253(17)30394-1 doi:10.1016/S2468-1253(17)30394-1. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/focus4-d
Report a problem with these data
Related trials
- Cetuximab β + FOLFIRI in RAS/BRAF wild-type colorectal cancer: Overall survival; Progression-free survival (BIRC-assessed)
- BEYOND: Progression-free survival at six months
- BREAKWATER: Overall survival
- Sequential vs upfront oxaliplatin in metastatic colorectal cancer: Overall survival
- SCOT (primary analysis): Disease-free survival; Overall survival
- HIPECT4 (final analysis): Disease-free survival; Locoregional control; Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials